The cannabis industry is witnessing a notable shift in consumer preferences towards edibles, particularly those infused with minor cannabinoids, as reported by BayMedica, a subsidiary of InMed Pharmaceuticals. The edible market's revenue saw a 5.4% increase in 2023, totaling $2.097 billion, underscoring the growing demand for these products. This trend is attributed to the therapeutic effects and consistent experiences that edibles offer, making them a preferred choice for many consumers.
While THC and CBD have dominated the cannabis conversation, there's an increasing curiosity around non-intoxicating minor cannabinoids. These compounds are gaining attention for their unique properties and potential health benefits, contributing to the expansion of the edible market. BayMedica's report highlights this evolution, pointing to a future where the product landscape is diversified by these lesser-known cannabinoids.
The acceptance of cannabis in society has paved the way for the popularity of edibles, which are products containing cannabinoids that can be consumed as food or drink. This shift not only reflects changing consumer preferences but also signals a broader acceptance of cannabis use for both recreational and therapeutic purposes. The implications of this trend are significant, suggesting a potential for further market growth and innovation in cannabis products.
For investors and industry stakeholders, the rise of minor cannabinoids in the edible market represents an opportunity to explore new product lines and cater to evolving consumer demands. The full report by BayMedica, available through InMed Pharmaceuticals' newsroom, provides deeper insights into this growing segment of the cannabis industry.
